Semaglutide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits
Authors' conclusion
Semaglutide confers robust, consistent multisystem benefits-including cardiovascular, hepatic, and renal protection-supporting its role as a transformative, disease-modifying therapy for metabolic disease beyond diabetes and obesity management. These findings support using semaglutide as a comprehensive, disease-modifying therapy for complex metabolic disorders, guiding clinicians to integrate it into patient-centered care for multisystem benefits beyond glycemic and obesity control.
Study context
- Population
- Adults (≥18 years) in RCTs with ≥24-week follow-up; mean age 54.2 years; BMI 34.8 kg/m²
- Participants
- 36,847 adults35 RCTs
- Comparison
- Semaglutide vs placebo or active comparators
- Outcome
- MACE, resolution of MASH, and composite renal endpoints
Methodological detailsPRISMA 2020, RoB 2 and GRADE assessment
- PRISMA 2020
- RoB 2 and GRADE assessment
Pooled result
As reported in the abstract
MACE reduction, RR
16%, RR 0.84
95% CI 0.77–0.92
MASH resolution, RR
62.9%, RR 1.84
95% CI 1.49–2.27
Renal protection, HR (95% CI 0.68-0.85)
HR 0.76
Further pooled results
| Outcome | Difference (%) (95% CI) | |
|---|---|---|
| HbA1c | −1.52 (−1.60 to −1.44) | |
| −2−101Difference, % (linear scale) |
| Outcome | Difference (kg) (95% CI) | |
|---|---|---|
| Weight | −12.4 (−13.0 to −11.8) | |
| −20−10010Difference, kg (linear scale) |
Vascular function, body composition, quality of life
- Walking distance
- +87 m
- Fat-to-lean ratio
- 87:13
- SF-36
- +3.8 points
Safety
- No increase was observed in psychiatric or cancer risk
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →